AYTU
Aytu BioPharma
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 0
High Gross Profit Margin
EPS Beats Expectation
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About AYTU
Aytu Biopharma, Inc.
A pharmaceutical company that develops novel products in the field of urology in the United States
7900 East Union Avenue, Suite 920, Denver, Colorado 80237
--
Aytu BioPharma, Inc., was originally established in Colorado, USA on August 9, 2002. The company is a pharmaceutical company focused on commercializing novel therapies and consumer healthcare products. The Company operates through two business segments: (i) the Rx segment, which includes prescription drug products; and (ii) the Consumer Healthcare segment, which includes a variety of consumer healthcare products.
Company Financials
EPS
AYTU has released its 2025 Q2 earnings. EPS was reported at -0.28, versus the expected -0.06, missing expectations. The chart below visualizes how AYTU has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
AYTU has released its 2025 Q2 earnings report, with revenue of 16.22M, reflecting a YoY change of -13.48%, and net profit of 788.00K, showing a YoY change of 458.18%. The Sankey diagram below clearly presents AYTU’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
